78%Confidence
0Views
FDASource
2026-03-14Date
Summary
LEO Pharma recalls Adbry autoinjectors due to wool fiber contamination, a sterility issue that could impact patient safety for this atopic dermatitis treatment. While limited to one unit, it raises concerns about LEO's manufacturing controls and may affect market confidence.
Actionable: Monitor LEO Pharma's response to the recall and assess competitor biologics like Dupixent for potential market share gains.
AI Confidence: 78%
Data Points
firmLEO PHARMA INC
classificationClass II
statusOngoing
distributionNationwide in the USA
productAdbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single do
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now